Kevin Robert Lind Net Worth

The estimated Net Worth of Kevin Robert Lind is at least 796 千$ dollars as of 13 February 2020. Kevin Lind owns over 4,500 units of Arena Pharmaceuticals Inc stock worth over 795,620$ and over the last 8 years Kevin sold ARNA stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kevin Lind ARNA stock SEC Form 4 insiders trading

Kevin has made over 2 trades of the Arena Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Kevin exercised 4,500 units of ARNA stock worth 119,700$ on 13 February 2020.

The largest trade Kevin's ever made was exercising 6,300 units of Arena Pharmaceuticals Inc stock on 14 October 2019 worth over 629,937$. On average, Kevin trades about 1,543 units every 17 days since 2016. As of 13 February 2020 Kevin still owns at least 7,957 units of Arena Pharmaceuticals Inc stock.

You can see the complete history of Kevin Lind stock trades at the bottom of the page.

What's Kevin Lind's mailing address?

Kevin's mailing address filed with the SEC is C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO, CA, 92121.

Insiders trading at Arena Pharmaceuticals Inc

Over the last 21 years, insiders at Arena Pharmaceuticals Inc have traded over 9,243,184$ worth of Arena Pharmaceuticals Inc stock and bought 78,040 units worth 252,505$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Manmeet Singh Soni、Garry Arthur Neil. On average, Arena Pharmaceuticals Inc executives and independent directors trade stock every 39 days with the average trade being worth of 3,133,387$. The most recent stock trade was executed by Amit Munshi on 16 August 2021, trading 1,000 units of ARNA stock currently worth 48,190$.

What does Arena Pharmaceuticals Inc do?

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas

Complete history of Kevin Lind stock trades at Arena Pharmaceuticals Inc

Arena Pharmaceuticals Inc executives and stock owners

Arena Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Amit Munshi,
  Director, President and Chief Executive Officer
• Vincent Aurentz,
  Executive Vice President and Chief Business Officer
• Robert Lisicki,
  Executive Vice President and Chief Commercial Officer
• Amit D. Munshi M.B.A.,
  Pres, CEO & Director
• Vincent E. Aurentz,
  Exec. VP & Chief Bus. Officer
• Dr. Christopher H. Cabell FACC, M.D., MHS,
  Advisor
• Laurie D. Stelzer,
  Exec. VP & CFO
• Joan Schmidt,
  Exec. VP, Gen. Counsel & Sec.
• Tina Nova,
  Independent Chairman of the Board
• Jennifer Jarrett,
  Independent Director
• Randall Woods,
  Independent Director
• Jayson Dallas,
  Independent Director
• Manmeet Soni,
  Independent Director
• Kieran Gallahue,
  Independent Director
• Oliver Fetzer,
  Independent Director
• Garry Neil,
  Independent Director
• Katharine Knobil,
  Director
• Joan Schmidt,
  Executive Vice President, General Counsel, Secretary
• Laurie Stelzer,
  Chief Financial Officer, Executive Vice President
• Patrick Malloy,
  VP of Investor Relations & Corp. Communications
• Megan E. Knight,
  Director of Investor Relations
• Dr. Lamine Mbow Ph.D.,
  Sr. VP & Chief Scientific Officer
• Dr. Douglas A. Bakan Ph.D.,
  Exec. VP of Technical Operations
• Harry F Jr Hixson,
  Director
• Maurice James Mezzino,
  SVP, Corporate Development
• Phillip M Schneider,
  Director
• Preston Klassen,
  EVP and CMO
• Steven W Spector,
  EVP, General Counsel & Sec
• Scott H Bice,
  Director
• Kevin Robert Lind,
  Executive VP and CFO
• Christine Anna White,
  Director
• Donald D Belcher,
  Director
• Nawal Ouzren,
  Director
• Frederick Frank,
  
• Mark N Lampert,
  Director
• Robert Hoffman,
  SVP, Finance and CFO
• Partners L P/Ilbiotechnolog...,
  
• James Laforce,
  Director
• Jennifer Kathleen Bielasz,
  VP, Accounting & Controller
• K A Ajit Simh,
  VP, Quality Systems
• Jack Lief,
  Chairman, President and CEO
• Craig Michael Audet,
  SVP, Opn & Head Glob Reg Afrs
• Duke K Bristow,
  Director
• Robert L Toms,
  Director
• Paul W Maffuid,
  VP, Pharmaceutical Development
• Joyce H Williams,
  VP, Drug Development
• Partners L P/Ilbvf Inc/Ilbi...,
  
• Nigel R A Beeley,
  VP, Chief Chemical Officer
• Joseph F Mooney,
  Chief Financial Officer
• Derek T Chalmers,
  Vice President, Research
• Louis J Scotti,
  VP, Marketing and Bus Dev
• Dominic P Behan,
  EVP & Chief Scientific Officer
• James Edeerfield Capital Lp...,
  
• Louis J Jr Lavigne,
  Director
• William R Jr Shanahan,
  SVP & Chief Medical Officer
• Christopher Cabell,
  EVP, Head of R&D, and CMO
• Steven J Schoch,
  Director
• Douglas J. Manion,
  EVP Research & Development